Cost Analysis of Varenicline Versus Bupropion, Nicotine Replacement Therapy, and Unaided Cessation in Nicaragua

References

• . World Health Organization. WHO Report on the global tobacco epidemic, 2009: implementing smoke-free environments. http://myweb.polyu.edu.hk/~hswhocc/resource/PCH/report_tobacco_epi_09.pdf. Accessed November 1, 2010
   Google Scholar
• . US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004
   Google Scholar
• . Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;(1):CD003041
   Google Scholar
• . Teo KK, Ounpuu S, Hawken S, ; INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368(9536):647–658
   PubMed Web of Science ®Google Scholar
• . Listado de medicamentos vigentes en Nicaragua. http://www.minsa.gob.ni/index.php?option=com_remository&Itemid=52&func=select&id=1869. Accessed January 8, 2012
   Google Scholar
• . Cuadra JA; La Asociación Nicaragüense de Neumología. Tabaquismo en Nicaragua, http://www.neumoytorax.com/jc_tabaquismo_nicaragua.pdf. Accessed November 20, 2010
   Google Scholar
• . Knight C, Howard P, Baker CL, Marion JP. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. 2010;13(2):209–214
   PubMed Web of Science ®Google Scholar
• . Index Mundi. Nicaragua GDP—per capita (PPP) http://www.indexmundi.com/nicaragua/gdp_per_capita_%28ppp%29.html. Accessed January 20, 2011
   Google Scholar
• . Bolin K, Mörk AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy—cost-utility results for Sweden 2003. Respir Med. 2008;102(5):699–710
   PubMed Web of Science ®Google Scholar
• . Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin. 2010;26(3):549–560
   PubMed Web of Science ®Google Scholar
• . Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497–511
   PubMed Web of Science ®Google Scholar
• . Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24(1):51–61
   PubMed Web of Science ®Google Scholar
• . Sanitary Products and Spanish Medications Agency. Technical File, Nicorette transdermic patches. Ministry of Public Health, Social Politics and Equality, Madrid. [Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica. Parches transdérmicos de nicotina. Ministerio de Sanidad, Política Social e Igualdad, Madrid.]
   Google Scholar
• . National PBM Drug Monograph. Varenicline (Chantix^$tM). http://www.pbm.va.gov/Clinical%20Guidance/Drug%20Monographs/Varenicline.pdf. December 2006. Accessed November 20, 2010
   Google Scholar
• . Index Mundi. Nicaragua demographics profile 2012. http://www.indexmundi.com/nicaragua/demographics_profile.html. Accessed November 20, 2010
   Google Scholar
• . Wetter D, Cofta-Gunn L, Fouladi R, Cinciripini P, Sui D, Gritz E. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med. 2004;39(6);1556–1163
   Web of Science ®Google Scholar
• . Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res. 2002;4(1):95–100
   PubMedGoogle Scholar
• . Lutz-Ramírez M, Heibron E. Cost-effectiveness of varenicline versus all interventions for quitting smoking cessation in the adult population of Costa Rica using the BENESCO model. Acta Méd Costarric. 2010;52(4). http://www.scielo.sa.cr/scielo.php?pid=S0001-60022010000400006&script=sci_arttext. Accessed January 23, 2011
   Google Scholar
• . Hospital “Antonio Lenin Fonseca” un Centro de Atención a la Nación. http://elinformativonica.com/index.php?option=com_content&task=view&id=1768&Itemid=47. Published June 8, 2010. Accessed January 8, 2012
   Google Scholar
• . National Institute of Public Health. Council of General Health Regulations. General Management of Prioritization. Interinstitutional Committee of the Basic Resources of the Health Sector. Guide for the development of economic evaluation studies for the update of the Basic Resources of the Health Sector in Mexico, http://www.csg.salud.gob.mx/descargas/pdfs/cuadro_basico/GUxA_EVAL_ECON25082008_2_ech.pdf. August 2008. Accessed May 23, 2011
   Google Scholar
• . Reus VI, Obach RS, Coe JW, . Varenicline: new treatment with efficacy in smoking cessation. Drugs Today (Barc). 2007;43(2):65–75
   PubMed Web of Science ®Google Scholar
• . Schnoll RA. Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs. 2006;11(3):429–444
   PubMedGoogle Scholar
• . Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146
   Google Scholar
• . McDowell I, Mothersill K, Rosser W, Hartman R. A randomized trial of three approaches to smoking cessation. Can Fam Physician. 1985;31:845–851
   PubMed Web of Science ®Google Scholar
• . Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–637
   PubMed Web of Science ®Google Scholar
• . Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–393
   PubMed Web of Science ®Google Scholar
• . Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics. 2001;19(8):855–863
   PubMed Web of Science ®Google Scholar
• . Hay JW, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics. 2005;23(2):133–141
   PubMed Web of Science ®Google Scholar
• . Fryback DG, Dasbach EJ, Klein R, . The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89–102
   PubMed Web of Science ®Google Scholar
• . Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191–200
   PubMed Web of Science ®Google Scholar
• . Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology. 2000;39(5):835–841
   PubMed Web of Science ®Google Scholar
• . World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Table: threshold values for intervention cost-effectiveness by region. http://www.who.int/choice/costs/CER_levels/en/index.html. Accessed November 20, 2010
   Google Scholar
• . Igarashi A, Takuma H, Fukuda T, Tsutani K. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics. 2009;27(3):247–261
   PubMed Web of Science ®Google Scholar
• . Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig. 2009;29(10):655–665
   PubMed Web of Science ®Google Scholar
• . Mould JF, Contreras I. Cost-effective analysis of varenicline (Champix) versus nicotine patch in treatment for smoking cessation in Mexico [in Spanish]. Pharmacoeconomics—Spanish Research Articles. 2009;6(1):22–32
   Google Scholar